These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 34451449)
1. Suspected Severe Malaria in a Sudanese Patient Affected by Sickle Cell Disease Who Was Treated with Hydroxyurea. Chiopris G; Maccario S; Eisa Artaiga TH; Ibrahim Mohamed A; Valenti M; Esposito S Pathogens; 2021 Aug; 10(8):. PubMed ID: 34451449 [TBL] [Abstract][Full Text] [Related]
2. Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum. Mwaiswelo RO; Mawala W; Iversen PO; de Montalembert M; Luzzatto L; Makani J Malar J; 2020 Apr; 19(1):165. PubMed ID: 32334583 [TBL] [Abstract][Full Text] [Related]
3. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. Aneni EC; Hamer DH; Gill CJ Trop Med Int Health; 2013 Mar; 18(3):313-27. PubMed ID: 23320577 [TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges. Dexter D; McGann PT Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823 [TBL] [Abstract][Full Text] [Related]
8. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Menendez C; Kahigwa E; Hirt R; Vounatsou P; Aponte JJ; Font F; Acosta CJ; Schellenberg DM; Galindo CM; Kimario J; Urassa H; Brabin B; Smith TA; Kitua AY; Tanner M; Alonso PL Lancet; 1997 Sep; 350(9081):844-50. PubMed ID: 9310602 [TBL] [Abstract][Full Text] [Related]
9. Malaria in patients with sickle cell anaemia: burden, risk factors and outcome at the Laquintinie hospital, Cameroon. Eleonore NLE; Cumber SN; Charlotte EE; Lucas EE; Edgar MML; Nkfusai CN; Geh MM; Ngenge BM; Bede F; Fomukong NH; Kamga HLF; Mbanya D BMC Infect Dis; 2020 Jan; 20(1):40. PubMed ID: 31937250 [TBL] [Abstract][Full Text] [Related]
14. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184 [TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE; N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa. Bello-Manga H; DeBaun MR; Kassim AA Expert Rev Hematol; 2016 Nov; 9(11):1031-1042. PubMed ID: 27677923 [TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes? Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936 [TBL] [Abstract][Full Text] [Related]
19. Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study. Koehl B; Aupiais C; Schinckel N; Mornand P; Odièvre MH; Niakate A; Brousse V; Ithier G; Missud F; Holvoet L; Benkerrou M; Sorge F; Faye A J Travel Med; 2021 Apr; 28(3):. PubMed ID: 33550421 [TBL] [Abstract][Full Text] [Related]